Sai Parenterals IPO Opens Today: Price Band Set at ₹372–392, Key Details for Investors

The Initial Public Offering (IPO) of Sai Parenterals Limited has opened for subscription today, offering investors an opportunity to participate in a growing pharmaceutical formulations and CDMO business. With a price band of ₹372–392 per share and strong anchor investor participation, the ₹409-crore IPO is attracting significant market attention.

Sai Parenterals IPO: Issue Size and Key Dates

Sai Parenterals aims to raise approximately ₹409 crore through its public issue. The IPO opened on March 24, 2026, and will close on March 27, 2026.

The price band for the issue has been fixed at ₹372 to ₹392 per equity share. Investors can bid for a minimum lot size of 38 shares, making it accessible to retail investors while also appealing to institutional participants.

The IPO follows the book-building route, where investor demand determines the final price within the specified range.

Breakdown of IPO Structure

The IPO consists of two major components:

Fresh Issue and Offer for Sale (OFS)

• Fresh issue of equity shares worth up to ₹285 crore

• Offer for sale (OFS) of up to 31,57,880 shares by existing shareholders

The OFS portion includes shares sold by notable investors such as Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, Devendra Chawla, Bhanwar Lal Chandak, Ashish Maheshwari, and others.

Investor Allocation Categories

As per regulatory guidelines, the allocation of shares is divided into three categories:

• Up to 50% for Qualified Institutional Buyers (QIBs)

• Minimum 15% for Non-Institutional Investors (NIIs)

• Minimum 35% for Retail Individual Investors (RIIs)

This structured allocation ensures balanced participation across investor segments.

Strong Participation from Anchor Investors

Ahead of the IPO opening, Sai Parenterals successfully raised ₹122 crore from anchor investors, reflecting strong institutional confidence.

The company allocated over 31 lakh equity shares at ₹392 per share to leading institutional investors, including:

• Morgan Stanley (Asia Singapore arm)

• Kotak Mahindra Life Insurance Company

• Kotak Life Sciences Fund

• India Emerging Funds Limited

• Quant Mutual Fund

This robust anchor participation is often viewed as a positive signal for market sentiment.

Utilisation of IPO Proceeds

The funds raised from the fresh issue will be primarily used to support the company’s growth and expansion strategies.

Expansion of Global Formulations Business

A significant portion of the proceeds will be directed toward strengthening the company’s global formulations segment. This includes enhancing manufacturing capabilities and expanding product offerings in regulated international markets.

Boosting CDMO Capabilities

The company also plans to invest in its Contract Development and Manufacturing Organisation (CDMO) segment, focusing on both injectable products and oral solid dosage forms.

These investments aim to position Sai Parenterals as a reliable partner for global pharmaceutical companies.

Company Overview and Business Model

Sai Parenterals operates as a diversified pharmaceutical formulations company with capabilities spanning research, development, and manufacturing.

Wide Range of Therapeutic Offerings

The company’s portfolio covers multiple therapeutic areas, including:

• Cardiovascular diseases
• Neuropsychiatry
• Anti-diabetic treatments
• Respiratory care
• Antibiotics
• Gastroenterology
• Vitamins, minerals, and supplements (VMS)
• Analgesics and dermatology

It manufactures products across various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.

Specialisation in Injectable Manufacturing

Sai Parenterals has strong expertise in sterile injectable manufacturing, especially for critical care and antibiotics.

Its product range includes dry powder injections, prefilled syringes, ampoules, and vials—segments that require high regulatory compliance and technical expertise.

Manufacturing Footprint and Global Presence

The company has built a solid manufacturing base in India, with a focus on quality and scalability.

Manufacturing Facilities

Sai Parenterals owns and operates five manufacturing units in India, four of which are located in Hyderabad, Telangana.

The company strengthened its infrastructure by acquiring two internationally accredited manufacturing units, which marked the beginning of its export journey in FY2023.

Export Markets

The company exports its products to several regulated and semi-regulated markets, including:

• Australia and New Zealand
• Southeast Asia
• Middle East
• Africa

These international operations are supported through a network of distributors.

Strategic International Expansion

Through its Singapore-based subsidiary, Sai Parenterals Pte Limited, the company has entered into strategic agreements with global partners, including UK-based firms, to expand its footprint in international markets.

Financial Performance Overview

Sai Parenterals has demonstrated consistent growth in its financial performance over recent years.

Revenue Growth

• ₹163 crore revenue in FY25
• ₹96.7 crore revenue in FY23
• ₹86.9 crore revenue for the six months ending September 30, 2025

Profitability

• ₹14.4 crore net profit in FY25
• ₹4.37 crore net profit in FY23
• ₹7.7 crore net profit for the six months ending September 2025

The steady increase in revenue and profits highlights the company’s improving operational efficiency and market expansion.

IPO Management and Registrar Details

The IPO is being managed by Arihant Capital Markets, which is acting as the book-running lead manager.

The registrar for the issue is Bigshare Services Private Limited, responsible for handling investor applications and allotment processes.

What This IPO Means for Investors

Sai Parenterals’ IPO presents an opportunity for investors to gain exposure to the pharmaceutical sector, particularly in the high-growth CDMO and injectable segments.

The company’s expanding global presence, strong anchor backing, and improving financials make it an attractive proposition. However, investors should also consider market conditions, valuation, and sector-specific risks before making investment decisions.

Conclusion

The opening of Sai Parenterals’ IPO marks an important milestone in the company’s growth journey. With a well-defined expansion strategy, strong institutional support, and a diversified product portfolio, the company is positioning itself for long-term growth.

As the IPO progresses, investor response will play a key role in determining its success in the primary market.